Adverse event summary
| . | V114 (N = 69) . | PCV13 (N = 34) . |
|---|---|---|
| n (%) . | n (%) . | |
| Participants with: | ||
| One or more AEs | 56 (81.2) | 27 (79.4) |
| Injection-site AEs | 48 (69.6) | 26 (76.5) |
| Systemic AEs | 42 (60.9) | 19 (55.9) |
| Vaccine-related AEs∗ | 51 (73.9) | 26 (76.5) |
| Injection-site AEs | 48 (69.6) | 26 (76.5) |
| Systemic AEs | 28 (40.6) | 7 (20.6) |
| Serious AEs | 13 (18.8) | 8 (23.5) |
| Serious vaccine-related AEs | 0 (0.0) | 0 (0.0) |
| Deaths | 0 (0.0) | 0 (0.0) |
| . | V114 (N = 69) . | PCV13 (N = 34) . |
|---|---|---|
| n (%) . | n (%) . | |
| Participants with: | ||
| One or more AEs | 56 (81.2) | 27 (79.4) |
| Injection-site AEs | 48 (69.6) | 26 (76.5) |
| Systemic AEs | 42 (60.9) | 19 (55.9) |
| Vaccine-related AEs∗ | 51 (73.9) | 26 (76.5) |
| Injection-site AEs | 48 (69.6) | 26 (76.5) |
| Systemic AEs | 28 (40.6) | 7 (20.6) |
| Serious AEs | 13 (18.8) | 8 (23.5) |
| Serious vaccine-related AEs | 0 (0.0) | 0 (0.0) |
| Deaths | 0 (0.0) | 0 (0.0) |
Reported AEs include nonserious AEs within 14 days following vaccination and serious AEs within 6 months following vaccination.
Determined by the investigator to be related to the vaccine.